Treatment of hemophilia: From plasma derivative to gene therapy;LE TRAITEMENT DE L'HEMOPHILIE: DES DERIVES DU PLASMA A LA THERAPIE GENIQUE

Hematologie

Volumn 2, Issue 1, 1996, Pages 17-27

  Négrier, Claude ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

factor IX; factor VIII; gene therapy; hemophilia

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9; BLOOD DERIVATIVE; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; GENE THERAPY; HEMOPHILIA; HEPATITIS; HUMAN; REVIEW; VIRUS INFECTION;

EID: 0030065824     PISSN: 12647527     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Hopff F. Ueber die Haemophilie oder die erbliche Anlage zu tödtlichen Blutungen. Inaugural-Abhandlung. Würzburg: CW Becker, 1828.
2. Otto JC. An account of an haemorrhagic disposition existing in certain families. Med Reposit 1803; 6: 1-4.
3. Hayem G. Du sang et de ses altérations anatomiques. Paris, 1889.
4. Pavlovsky A. A contribution to the pathogenesis of hemophilia. Blood 1947; 2: 185-8.
5. Biggs R, Douglas AS, Macfarlane RG, Dacie JV, Pitney WR, Merskey C, O'Brien JR. Christmas disease. A condition previously mistaken for haemophilia. Brit Med J 1952; 2: 1378-82.
6. Gitschier J, Wood WI, Goralka TM, Wion KL, Chen EY, Eaton DH, Vehar GA, Capon DJ, Lawn RM. Characterization of the human factor VIII gene. Nature 1984; 312: 326-30.
7. Yoshitake S, Schach BG, Foster DC, Dovie EW, Kurachi K. Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochemistry 1985; 24: 3736-50.
8. Lane S. Haemorrhagic diathesis. Successful transfusion of blood. Lancet 1840; 1: 185-8.
9. Weil PE. L'hémophilie, pathogénie et sérothérapie. Presse Med 1905; 13: 673-6.
10. Feissly R. Recherches expérimentales sur la correction in vivo de la coagulabilité sanguine chez l'hémophile. Bull Mem Soc Med Hop Paris 1924; 48: 1739-42.
11. Patek AJ, Taylor FHL. Hemophilia, II. Some properties of a substance obtained from normal human plasma effective in accelerating coagulation or hemophilic blood. J Clin Invest 1937; 16: 113-24.
12. Cohn EJ, Strong IE, Hughes WI, Mulford DJ, Ashworth JN, Melin M, Taylor HL. Preparation and properties of serum and plasma proteins, IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Amer Chem Soc 1946; 68: 459.
13. Brinkhous KM. Clotting defect in hemophilia : deficiency in a plasma factor required for platelet utilization. Proc Soc Exp Biol Med 1947; 66: 117-20.
14. Pool JG, Hershgold EJ, Pappenhagen AR. High-potency antihaemophilic factor concentrate prepared from cryoglobulin precipitate. Nature 1964; 203 : 312.
15. White GC, McMillan CW, Kingdon HS, Shoemaker CB. Use of recombinant antihemophilic factor in the treatment of Iwo patients with classic hemophilia. N Engl J Med 1989; 320: 166-70.
16. Keith JC Jr, Ferranti TJ, Misra B, Frederick T, Rup B, McCarthy K, Faulkner R, Bush L, Schaub RG. Evaluation of recombinant human factor IX: pharmacokinetic studies in the rat and the dog. Thromb Haemost 1994; 73 : 101-5.
17. Shopnick RI, Brettler DB, Kazemi M, Gomperts ED. Anaphylaxis following the use of recombinant factor VIII (Recombinate ©, Baxter/Hyland). Blood 1994; 15 : 1855 (abst).
18. Seremetis SV, Aledort IM, Bergman GE, Bona R, Bray G, Brettler D, Eyster ME, Kessler C, Lau TS, Lusher J, Rickles F. Three-year randomized study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-sero-positive haemophiliacs: effects on immune status. Lancet 1993; 342: 700-3.
19. + counts before and after switching to monoclonal high-purity factor VIII concentrate in HIV-infected haemophilic patients. Thromb Haemost 1994; 72: 214-7.
20. Troisi CL, Hollinger BF, Hoots KW, Contant C, Gill J, Ragni M, Parmley R, Sexaeur C, Gomperts E, Buchanan G, Schwartz B, Adair S, Fields H. A multicenter study of viral hepatitis in a United States Hemophilic population. Blood 1993; 2: 412-8.
21. Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The multicenter hemophilia cohort study. J Acquir Immune Defic Syndr 1993; 6 : 602-10.
22. Ragni MV, Bontempo FA, Myers DJ, Kiss JE, Oral A. Hemorrhagic sequelae of immune thrombocytopenic purpura in human immunodeficiency virus-Infected hemophiliacs. Blood 1990; 75 : 1267-72.
23. Stieltjes N, Sultan Y, Rothschild C, Torchet AAF, Laurian Y, Navarro R, Fressinaud E, Parquet Gernez A, Fonlupt J, Berthier AM and the French hemophilia study group. Long-term survival of HIV-infected patients with hemophilia. Haemophilia 1995; 1: 33-6.
24. Mannucci PM. Outbreak of hepatitis A among Italian patients with haemophilia. Lancet 1992; 339 : 819.
25. Azzi A, Ciapi S, Zakrzewska K, Morfini M, Moriani G, Mannucci PM. Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates. Am J Hematol 1992; 39 : 228-30.
26. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS and the Kogenate® previously untreated patient study group. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A : safety, efficacy and development of inhibitors. N Engl J Med 1993; 328 : 453-9.
27. Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shopiro A, Scheibel E, White III G, Lee M and the Recombinate study group A multicenter study of recombinant factor VIII (Recombinate®): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. Blood 1994; 83 : 2428-35.
28. Addiego J, Kasper C, Abildgaard C, Hilgartner M, Lusher J, Glader B, Aledorf L. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet 1993; 342 : 462-4.
29. Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Güngör T, Krackhardt B, Kornhuber B. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992 ; 339 : 594-8.
30. Guérois C, Laurian Y, Rothschild C, Parquet-Gernez A, Duclos AM, Négrier C, Vicariot M, Fimbel B, Fressinaud E, Fiks-Sigaud M, Derlon A, Berthier AM, Gaillard S, Bertrand MA. Incidence of factor VIII inhibitor development in severe hemophilia A patients treated only with one brand of highly purified plasma-derived concentrate. Thromb Hoemost 1995; 73 : 215-8.
31. Scandella D. Human antibodies which inactivate factor VIII : their epitope specificity and biochemical and functional characteristics. Intern Journ Ped Hematol/Oncol 1994; 1 : 437-47.
32. Rosendaol FR, Nieuwenhuis HK, van den Berg HM, Heijboer H, Mauser-Bunschoten EP, van der Merr J, Smit C, Strengers PFW, Brièt É and the Dutch Hemophilia Study Group. A sudden increase in factor VIII inhibitor developement in multitransfused hemophilia A patients in the Netherlands. Blood 1993; 81 : 2180-6.
33. Martinowitz U, Schulman S, Gitel S, Horozawski H, Heim M, Varon D. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. Brit J Haematol 1992 ; 82 : 729-34.
34. Nilsson IM, Bemtarp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Int Med 1992 ; 232 : 25-32.
35. Mannucci PM, Vicente V, Alberca I, Sacchi E, Longo G, Harris AS, Lindquist A. Intravenous and subcutaneous administration of desmopressin (DDAVP) to hemophiliacs : pharmacokinetics and factor VIII responses. Thromb Haemost 1987 ; 58 : 10379.
36. Webster WP, Penick GD, Peacock EE, Brinkhous KM. Allotransplantation of spleen in hemophilia. NC Med J 1967; 28: 505-7.
37. Webster WP, Mandel SR, Reddick RL, Wagner JL, Penick GD. Orthotopic liver transplantation in canine hemophilia B. Am J Physiol 1974; 226 : 496-500.
38. Lewis JH, Bontempo FA, Spero JA, Ragni MV, Starzl TE. Liver transplantation in a hemophiliac. N Engl J Med 1985; 312 : 1189-90.
39. St Louis D, Verma IM. An alternative approach to somatic cell gene therapy. Proc Natl Acad Sci USA 1988 ; 85 : 3150-4.
40. Palmer TD, Thompson AR, Miller AD. Production of human factor IX in animals by genetically modified skin fibroblasts. Potential therapy for hemophilia B. Blood 1989; 73: 438-45.
41. Dai Y, Roman M, Navioux RK, Verma IM. Gene therapy via primary myoblasts : long-term expression of factor IX protein following transplantation in vivo. Proc Natl Acod Sci USA 1992 ; 89 : 10892-5.
42. Gerrard AJ, Hudson DL, Brownlee GG, Walt FM. Towards gene therapy for hemophilia B using primary human keratinocytes. Nature Genet 1993 ; 3 : 180-3.
43. Hoeben RC, Einerhand MPW, Brièt E, Van Ormondi H, Valeria D, Von der Eb Al. Toward gene therapy in haemophilia A : refrovirus-mediated transfer of a factor VIII gene into murine haematopoietic progenitor cells. Thromb Haemost 1992 ; 67 : 341-5.
44. Yao SN, Wilson JM, Nabel EG, Kurachi S, Hachiya HL, Kurachi K. Expression of human factor IX in rot capillary endothelial cells : toward somatic gene therapy for hemophilia B. Proc Natl Acad Sci USA 1991; 88 : 8101-5.
45. Kay MA, Rothenberg S, Landen CN, Bellinger DA, Leland F, Toman C, Finegold M, Thompson AR, Read MS, Brinkhous KM, Woo SLC. In vivo gene therapy of hemophilia B : sustained partial correction in factor IX-deficient dogs. Science 1993; 262 : 117-9.
46. Kay MA, Landen CN, Rothenberg SR, Taylor LA, Leland F, Wiehle S, Fang B, Bellinger D, Finegold M, Thompson AR, Read M, Brinkhous KM, Woo SLC. In vivo hepatic gene therapy : complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc Natl Acad Sci USA 1994 ; 91 : 2353-7.
47. Wagner E, Zatloukal K, Cotten M, Kirlappos H, Mechtler K, Curiel DT, Birnstiel ML Coupling of adenovirus to transferrin-porylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. Proc Natl Acad Sci USA 1992 ; 89 : 6099-103.
48. Cristiano RJ, Smith LC, Kay MA, Brinkley BR, Woo SLC. Hepatic gene therapy. Efficient gene delivery and expression in primary hepatocytes utilizing a conjugated adenovirus DNA complex. Proc Natl Acod Sci USA 1993 ; 90 : 11548-52.
49. Perales JC, Ferkol T, Beegen H, Ratnoff OD, Hanson RW. Gene transfer in vivo : sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake. Proc Natl Acad Sci USA 1994 ; 91 ; 4080-90.
50. Lu DR, Zhou JM, Zheng B, Qiu XF, Xue JL, Wang JM, Meng PL, Hon FL, Ming BH, Wang XP, Wang JP, Liang JJ, Jiang ZS. Stage I clinical trial of gene therapy for hemophilia B. Science in China 1993; 36 : 1342-51.
51. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazozian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nature Genet 1995 ; 10 : 119-21.